A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

Completed · Phase 3

Conditions studied: Crohn's Disease

In brief

An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\]).

Key facts

Study ID

NCT00160524

Run by

UCB Pharma SA

People needed

596

Starts

2004-07-01

Expected to finish

2012-08-01

Last updated by the study team

2018-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in either of the CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] clinical studies in which the subject completed the trial at Week 26. Subjects may have received active or placebo or both treatments in the prior study
• Subjects must be able to understand the information provided to them and give written informed consent

You may not qualify if…

• Any exclusion criterion that would have prevented the subject's participation in the qualifying pivotal study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425], although the criterion that excludes previous participation in a clinical trial of Certolizumab Pegol does not apply. In addition there are no limits on the Clinical Disease Activity Index (CDAI) score at entry

Where it is running

• 45028 — Huntsville, Alabama, United States
• 45144 — Tucson, Arizona, United States
• 45095 — Orange, California, United States
• 45006 — San Diego, California, United States
• 45131 — San Diego, California, United States
• 45130 — Colorado Springs, Colorado, United States
• 45094 — Gainesville, Florida, United States
• 45029 — Jacksonville, Florida, United States
• 45087 — Miami, Florida, United States
• 45085 — Plantation, Florida, United States
• 45143 — Atlanta, Georgia, United States
• 45064 — Savannah, Georgia, United States
• 45138 — Columbus, Indiana, United States
• 45111 — Louisville, Kentucky, United States
• 45105 — Annapolis, Maryland, United States
• 45033 — Chevy Chase, Maryland, United States
• 45013 — Laurel, Maryland, United States
• 45057 — Plymouth, Minnesota, United States
• 45108 — Jefferson City, Missouri, United States
• 45031 — Lincoln, Nebraska, United States
• 45035 — Berlin, New Jersey, United States
• 45124 — Florham Park, New Jersey, United States
• 45018 — New Brunswick, New Jersey, United States
• 45009 — Great Neck, New York, United States
• 45102 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.